[Breaking] Samchundang Pharm (000250) Hits Lower Limit After Upper Limit Previous Day... Extreme Stock Price Volatility
Samchundang Pharm (000250) has plummeted from the upper limit to the lower limit in just one day, exhibiting a roller coaster-like stock price trajectory. As of
![[Breaking] Samchundang Pharm (000250) Hits Lower Limit After Upper Limit Previous Day... Extreme Stock Price Volatility](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F579545%2F36de0fb87055dd02%2Foriginal.webp&w=1920&q=75)
Samchundang Pharm (000250) has plummeted from the upper limit to the lower limit in just one day, exhibiting a roller coaster-like stock price trajectory.
As of 10:55 a.m. on the 21st, Samchundang Pharm entered the lower limit, trading at 167,500 won, down by the full daily price limit from the previous trading day.
Earlier in the day, during pre-market trading on the alternative trading system (NXT), the stock price hovered above the 280,000-won level, appearing to extend the previous day's strong momentum. However, a flood of sell orders immediately after the regular session opened erased all gains, ultimately pushing the stock down to the lower limit.
The stock had hit the upper limit the previous day, significantly boosting investor expectations, but the sentiment completely reversed in just one day. This displayed a pattern where pre-market bullish expectations gave way to a sharp contraction in investor sentiment during the regular session, flipping the direction of the stock price.
The market is now closely watching whether Samchundang Pharm's extreme volatility—swinging between the upper and lower limits in a single day—will persist in the short term. Future changes in supply and demand and the recovery of investor sentiment are cited as the key variables for the stock's trajectory.
[This article is not intended to solicit investment. All final investment decisions and responsibilities lie with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] April Bio Signs License-in Agreement with Qurigen for Dual-Target siRNA Metabolic Disease Therapeutics](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F579783%2F4e4da2bfb8f012b9%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Breaking] Samhyun (437730) Surges 19% in After-Hours NXT Trading, Recovering '30,000 Won Level'... Robot Stocks Rally](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581419%2F479dac739b049517%2Fvariants%2Fhero.webp&w=1920&q=75)

![[Breaking] KakaoPay Surges 7.68% in After-Hours NXT Trading... Buying Expands as It Recovers 40,000-Won Level in Regular Session](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581911%2Fa630da1c47d6049c%2Fvariants%2Fhero.webp&w=1920&q=75)